Publisher Health

This post was originally published on this site

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without immunosuppression. The company’s engineered cell product (UP421) uses a novel hypoimmune technology, and results of the first-in-human trial at 4 weeks showed pancreatic beta cell survival and function.

In a phase IIb/III trial of linsitinib for moderate to severe thyroid eye disease, treatment with the highest dose of the investigational, oral insulin-like growth factor 1 receptor inhibitor resulted in a statistically significant proptosis responder rate of 52% at week 24, according to maker Sling Therapeutics.

A database developed by researchers at Mass General Brigham ranked 50,000 processed foods and offers potential alternatives. (Nature Foods)

Investigational atumelnant, a once-daily oral adrenocorticotropic hormone receptor antagonist, significantly reduced morning androstenedione levels in a 12-week phase II study of people with congenital adrenal hyperplasia, said developer Crinetics Pharmaceuticals.

In the phase III OASIS 4 study, investigational elinzanetant significantly reduced frequency of moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with or at high risk of developing hormone receptor-positive breast cancer, said Bayer.

North Dakota became the first state to cover GLP-1 drugs for diabetes or obesity in Affordable Care Act marketplace plans. (Becker’s Payer Issues)

And Medicare will now cover tirzepatide (Zepbound) for obstructive sleep apnea in patients with obesity after last month’s FDA approval for that indication. (CNBC)

A novel injectable GLP-1/GIP receptor dual agonist (HRS9531) achieved a 21.1% placebo-adjusted weight loss at week 36 in a phase II trial of Chinese adults with obesity or overweight, said Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics.

A national survey by Orlando Health found that 56% of Americans didn’t know that bariatric surgery could boost fertility.

The FDA cleared Euroimmun’s automated chemiluminescence-based immunoassay test for free testosterone, said Revvity.

In new draft guidance for anti-obesity drug development, the FDA set an efficacy threshold of 5% weight loss over a year for future products. (Endpoints News)

Although Medicaid reimbursement for glucagon products for severe hypoglycemia increased from 2012 to 2023, less than 100,000 glucagon prescriptions were dispensed in 2023, likely only a fraction of the potential need based on the high-risk population. (JAMA)

Obesity at the time of a pediatric cancer diagnosis was independently associated with worse survival, especially for kids with acute lymphoblastic leukemia and central nervous system tumors, a large cohort study found. (Cancer)